CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan in the treatment of acute migraine attacks
DURHAM, N.C., June 9, 2010 /PRNewswire/ — CoLucid Pharmaceuticals, Inc., (“CoLucid”), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in- class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study. Results of this study will allow the selection of doses for pivotal Phase III studies of lasmiditan in the acute treatment of migraine, scheduled to begin in fourth quarter this year.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.